Vanguard Capital Management
STIM icon

Vanguard Capital Management’s Neuronetics STIM Stock Holding History

Vanguard Capital Management’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Sell
1,507,097
-540,878
-26% -$787K ﹤0.01% 3431
2026
Q1 		$2.97M Buy
+2,047,975
New +$3.25M ﹤0.01% 3240

Other funds holding STIM

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management's STIM Position: Q2 2026 in Review

Vanguard Capital Management reduced its Neuronetics (STIM) stake by 26% in Q2 2026, selling an estimated $787K and leaving 1,507,097 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #3431.

Vanguard Capital Management first reported a position in STIM in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.97M in Q1 2026. 86 funds tracked by Wall St. Rank hold STIM as of Q2 2026.

  • Vanguard Capital Management held 1,507,097 shares of Neuronetics worth $1.96M as of Q2 2026.
  • Vanguard Capital Management sold 540,878 Neuronetics shares in Q2 2026, an estimated $787K.
  • Neuronetics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3431 holding.
  • Vanguard Capital Management first reported a position in Neuronetics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Neuronetics position peaked at $2.97M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Neuronetics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.